Jump to main content
Jump to site search

Issue 37, 2014
Previous Article Next Article

Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors

Author affiliations

Abstract

Arsenic trioxide is a clinical drug that can be used to successfully treat acute promyelocytic leukemia. However, its therapeutic effect on solid tumors is limited because of the poor pharmacokinetics and dose-limiting toxicity. Here, we report a facile strategy to achieve high anticancer activity of arsenic trioxide by loading the nanoparticulate prodrug into hollow silica inorganic nanoparticles. Because of the appropriate size, pH sensitivity, and surface targeted modification, this smart nanosized drug system can deliver arsenic trioxide into cancer cells efficiently and exhibits much higher cytotoxicity to a variety of cancer cells than free arsenic trioxide. Moreover, this nanomedicine can further promote the differentiation and inhibit the migration of cancer cells. In vivo results suggest that this drug delivery system can significantly inhibit the growth of solid tumors without adverse side effects. This study highlights a feasible drug delivery strategy to expand the use of arsenic trioxide for the effective treatment of solid tumors.

Graphical abstract: Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors

Back to tab navigation

Supplementary files

Publication details

The article was received on 30 May 2014, accepted on 18 Jul 2014 and first published on 23 Jul 2014


Article type: Paper
DOI: 10.1039/C4TB00874J
Citation: J. Mater. Chem. B, 2014,2, 6313-6323
  •   Request permissions

    Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors

    Z. Zhao, H. Zhang, X. Chi, H. Li, Z. Yin, D. Huang, X. Wang and J. Gao, J. Mater. Chem. B, 2014, 2, 6313
    DOI: 10.1039/C4TB00874J

Search articles by author

Spotlight

Advertisements